Dysregulation of PTEN caused by the underexpression of microRNA‑130b is associated with the severity of lupus nephritis

Wu,Shupeng; Wang,Jing; Li,Fang

doi:10.3892/mmr.2018.8839

Dysregulation of PTEN caused by the underexpression of microRNA‑130b is associated with the severity of lupus nephritis

Authors:
- Shupeng Wu
- Jing Wang
- Fang Li
View Affiliations

Affiliations: Department of Rheumatism and Immunology, Tai'an Central Hospital, Tai'an, Shandong 271000, P.R. China, Department of Geriatric Diseases, Tai'an Central Hospital, Tai'an, Shandong 271000, P.R. China
Published online on: April 3, 2018 https://doi.org/10.3892/mmr.2018.8839
Pages: 7966-7972

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There are several reports in the literature regarding microRNA (miR)‑130b. It has been reported that miR‑130b is involved in several diseases. The present study aimed to understand the association between the levels of miR‑130b and lupus nephritis in patients. A total of 61 blood samples were collected and the expression level of miR‑130b was determined. The online miRNA database was then searched using the ‘seed sequence’ located within the 3'‑untranslated region of the target gene. Linear analysis and a luciferase assay were performed to understand the regulatory association between miR‑130b and phosphatase and tensin homolog (PTEN). In addition, reverse transcription‑polymerase chain reaction and western blot analyses were performed to examine the mRNA and protein expression levels of PTEN among individuals with lupus nephritis (n=28) and those without lupus nephritis (n=31), and in mesangial cells treated with scramble control, miR‑130b mimics, PTEN small interfering (si)RNA and miR‑130b inhibitors. In addition mesangial cells were treated with scramble control, miR‑130b mimics, PTEN siRNA and miR‑130b inhibitors to investigate the affect of miR‑130b and PTEN on the viability and apoptosis of mesangial cells. The results demonstrated that miR‑130b was downregulated in the hormone‑resistant group of lupus nephritis patients. PTEN was a virtual target of miR‑130b. There was a negative regulatory association between miR‑130b and PTEN. The mRNA and protein expression levels of PTEN were increased in the hormone‑resistant group. miR‑130b decreased the expression of PTEN. miR‑130b negatively interfered with the viability of mesangial cells and PTEN positively interfered with the viability of mesangial cells. miR‑130b accelerated apoptosis and PTEN inhibited apoptosis. Taken together, the results showed that miR‑130b was upregulated in the lupus nephritis group. PTEN was a virtual target of miR‑130b, and there was a negative regulatory association between miR‑130b and PTEN. miR‑130b and PTEN interfered with the viability and apoptosis of the mesangial cells.

View Figures

View References

1	Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, et al: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58:15–25. 2008. View Article : Google Scholar : PubMed/NCBI
2	Peng SL: Altered T and B lymphocyte signaling pathways in lupus. Autoimmun Rev. 8:179–183. 2009. View Article : Google Scholar : PubMed/NCBI
3	Hogan J and Radhakrishnan J: The treatment of minimal change disease in adults. J Am Soc Nephrol. 24:702–711. 2013. View Article : Google Scholar : PubMed/NCBI
4	Bertsias G, Gordon C and Boumpas DT: Clinical trials in systemic lupus erythematosus (SLE): Lessons from the past as we proceed to the future-the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus. 17:437–442. 2008. View Article : Google Scholar : PubMed/NCBI
5	Ceman S and Saugstad J: MicroRNAs: Meta-controllers of gene expression in synaptic activity emerge as genetic and diagnostic markers of human disease. Pharmacol Ther. 130:26–37. 2011. View Article : Google Scholar : PubMed/NCBI
6	Lorenzen JM, Haller H and Thum T: MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol. 7:286–294. 2011. View Article : Google Scholar : PubMed/NCBI
7	Farris AB and Colvin RB: Renal interstitial fibrosis: Mechanisms and evaluation. Curr Opin Nephrol Hypertens. 21:289–300. 2012. View Article : Google Scholar : PubMed/NCBI
8	Wang G, Kwan BC, Lai FM, Choi PC, Chow KM, Li PK and Szeto CC: Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. Am J Hypertens. 23:78–84. 2010. View Article : Google Scholar : PubMed/NCBI
9	Wang G, Kwan BC, Lai FM, Choi PC, Chow KM, Li PK and Szeto CC: Intrarenal expression of microRNAs in patients with IgA nephropathy. Lab Invest. 90:98–103. 2010. View Article : Google Scholar : PubMed/NCBI
10	Chung AC, Huang XR, Meng X and Lan HY: miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol. 21:1317–1325. 2010. View Article : Google Scholar : PubMed/NCBI
11	Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ and Natarajan R: MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA. 104:3432–3437. 2007. View Article : Google Scholar : PubMed/NCBI
12	Putta S, Lanting L, Sun G, Lawson G, Kato M and Natarajan R: Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol. 23:458–469. 2012. View Article : Google Scholar : PubMed/NCBI
13	Dai Y, Sui W, Lan H, Yan Q, Huang H and Huang Y: Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int. 29:749–754. 2009. View Article : Google Scholar : PubMed/NCBI
14	Lu J, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, Wang G, Li PK and Szeto CC: Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis. Nephrology (Carlton). 17:346–351. 2012. View Article : Google Scholar : PubMed/NCBI
15	Rabinovitch MB, Liberman and Fausto N: Plasma ribonuclease activity in human uremia. J Lab Clin Med. 53:563–568. 1959.PubMed/NCBI
16	Neal CS, Michael MZ, Pimlott LK, Yong TY, Li JY and Gleadle JM: Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant. 26:3794–3802. 2011. View Article : Google Scholar : PubMed/NCBI
17	Wang W, Mou S, Wang L, Zhang M, Shao X, Fang W, Lu R, Qi C, Fan Z, Cao Q, et al: Up-regulation of serum MiR-130b-3p level is associated with renal damage in early lupus nephritis. Sci Rep. 5:126442015. View Article : Google Scholar : PubMed/NCBI
18	Tan W, Gu Z, Shen B, Jiang J, Meng Y, Da Z, Liu H, Tao T and Cheng C: PTEN/Akt-p27(kip1) signaling promote the BM-MSCs senescence and apoptosis in SLE patients. J Cell Biochem. 116:1583–1594. 2015. View Article : Google Scholar : PubMed/NCBI
19	Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N and Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25:1271–1277. 1982. View Article : Google Scholar : PubMed/NCBI
20	Lamb EJ, Webb MC and O'Riordan SE: Using the modification of diet in renal disease (MDRD) and Cockcroft and Gault equations to estimate glomerular filtration rate (GFR) in older people. Age Ageing. 36:689–692. 2007. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Lv C, Zhou YH, Wu C, Shao Y, Lu CL and Wang QY: The changes in miR-130b levels in human serum and the correlation with the severity of diabetic nephropathy. Diabetes Metab Res Rev. 31:717–724. 2015. View Article : Google Scholar : PubMed/NCBI
23	Colangelo T, Fucci A, Votino C, Sabatino L, Pancione M, Laudanna C, Binaschi M, Bigioni M, Maggi CA, Parente D, et al: MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. Neoplasia. 15:1086–1099. 2013. View Article : Google Scholar : PubMed/NCBI
24	Egawa H, Jingushi K, Hirono T, Ueda Y, Kitae K, Nakata W, Fujita K, Uemura M, Nonomura N and Tsujikawa K: The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN. Sci Rep. 6:205742016. View Article : Google Scholar : PubMed/NCBI
25	Han X, Wang Y, Zhang X, Qin Y, Qu B, Wu L, Ma J, Zhou Z, Qian J, Dai M, et al: MiR-130b ameliorates murine lupus nephritis through targeting type I interferon pathway on resident renal cells. Arthritis Rheumatol. 68:2232–2243. 2016. View Article : Google Scholar : PubMed/NCBI
26	Govender D and Chetty R: Gene of the month: PTEN. J Clin Pathol. 65:601–603. 2012. View Article : Google Scholar : PubMed/NCBI
27	Li DM and Sun H: TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 57:2124–2129. 1997.PubMed/NCBI
28	Di Cristofano A and Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell. 100:387–390. 2000. View Article : Google Scholar : PubMed/NCBI
29	Xu WT, Yang Z and Lu NH: Roles of PTEN (Phosphatase and Tensin Homolog) in gastric cancer development and progression. Asian Pac J Cancer Prev. 15:17–24. 2014. View Article : Google Scholar : PubMed/NCBI
30	Myers MP and Tonks NK: PTEN: Sometimes taking it off can be better than putting it on. Am J Hum Genet. 61:1234–1238. 1997. View Article : Google Scholar : PubMed/NCBI
31	Ye B, Jiang LL, Xu HT, Zhou DW and Li ZS: Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis. Int J Immunopathol Pharmacol. 25:627–636. 2012. View Article : Google Scholar : PubMed/NCBI
32	Wu XN, Ye YX, Niu JW, Li Y, Li X, You X, Chen H, Zhao LD, Zeng XF, Zhang FC, et al: Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus. Sci Transl Med. 6:246ra992014. View Article : Google Scholar : PubMed/NCBI
33	Kaplan MJ: Apoptosis in systemic lupus erythematosus. Clin Immunol. 112:210–218. 2004. View Article : Google Scholar : PubMed/NCBI
34	Seery JP, Cattell V and Watt FM: Cutting edge: Amelioration of kidney disease in a transgenic mouse model of lupus nephritis by administration of the caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-(beta-o-methyl)-fluoromethylketone. J Immunol. 167:2452–2455. 2001. View Article : Google Scholar : PubMed/NCBI
35	Nakajima A, Hirai H, Kayagaki N, Yoshino S, Hirose S, Yagita H and Okumura K: Treatment of lupus in NZB/W F1 mice with monoclonal antibody against Fas ligand. J Autoimmun. 14:151–157. 2000. View Article : Google Scholar : PubMed/NCBI
36	Schaub FJ, Han DK, Liles WC, Adams LD, Coats SA, Ramachandran RK, Seifert RA, Schwartz SM and Bowen-Pope DF: Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med. 6:790–796. 2000. View Article : Google Scholar : PubMed/NCBI
37	Lenda DM, Kikawada E, Stanley ER and Kelley VR: Reduced macrophage recruitment, proliferation, and activation in colony-stimulating factor-1-deficient mice results in decreased tubular apoptosis during renal inflammation. J Immunol. 170:3254–3262. 2003. View Article : Google Scholar : PubMed/NCBI
38	Scheid MP and Woodgett JR: Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 546:108–112. 2003. View Article : Google Scholar : PubMed/NCBI
39	Deane JA and Fruman DA: Phosphoinositide 3-kinase: Diverse roles in immune cell activation. Annu Rev Immunol. 22:563–598. 2004. View Article : Google Scholar : PubMed/NCBI
40	Cantley LC and Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA. 96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI